Summit Therapeutics Inc.
SMMT
Rang in Aktien
#1662
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Aktienkurs
$16.14
Marktkapitalisierung
$12.87B
Veränderung (1 Tag)
3.65%
Veränderung (1 Jahr)
-19.47%
Land
US
Handel Summit Therapeutics Inc. (SMMT)
Kategorie
Healthcare
Gewinn für Summit Therapeutics Inc. (SMMT)
Gewinn im Jun 2026 TTM: $-856.04M
Laut den aktuellen Finanzberichten von Summit Therapeutics Inc. betragen die aktuellen Gewinne des Unternehmens $-856.04M. Im Jahr 2023 erzielte das Unternehmen einen Gewinn von $-615.87M, ein Rückgang im Vergleich zu dem Gewinn im Jahr 2022, der $-78.78M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Summit Therapeutics Inc. von 2004 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $-856.04M | 286.80% |
| 2024 | $-221.32M | -64.06% |
| 2023 | $-615.87M | 681.74% |
| 2022 | $-78.78M | -11.08% |
| 2021 | $-88.60M | 67.46% |
| 2020 | $-52.91M | 40.45% |
| 2019 | $-37.67M | -21.65% |
| 2018 | $-48.08M | 18.85% |
| 2017 | $-40.45M | 22.47% |
| 2016 | $-33.03M | 73.25% |
| 2015 | $-19.07M | 4.94% |
| 2014 | $-18.17M | 58.92% |
| 2013 | $-11.43M | 54.03% |
| 2012 | $-7.42M | -50.39% |
| 2011 | $-14.96M | 0.25% |
| 2010 | $-14.92M | -44.98% |
| 2009 | $-27.12M | -37.83% |
| 2008 | $-43.63M | 223.51% |
| 2007 | $-13.49M | 249.34% |
| 2006 | $-3.86M | 1,451.88% |
| 2005 | $-248.74K | 226.26% |
| 2004 | $-76.24K | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| $5.27B | -716.20% |
US
|
|
| $-3.09B | 260.61% |
US
|
|
| $-4.02B | 369.16% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -327.87% |
NL
|
